公开(公告)号：US20190127479A1

公开(公告)日：2019-05-02

申请号：US16177239

申请日：2018-10-31

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K9/00 ,  A61K39/395

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US11618787B2

公开(公告)日：2023-04-04

申请号：US16177239

申请日：2018-10-31

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61K39/395 ,  A61P35/00 ,  A61K31/573 ,  A61K31/495 ,  A61K31/4439 ,  A61K31/69 ,  A61K9/00 ,  A61K31/454 ,  A61K39/00

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US20220275101A1

公开(公告)日：2022-09-01

申请号：US17667656

申请日：2022-02-09

Applicant: Janssen Biotech, Inc.

Inventor： Jordan Schecter

IPC: C07K16/28 ,  A61K31/573 ,  A61K9/00 ,  A61K45/06 ,  A61K38/47

Abstract: The present invention relates to methods of achieving a complete hematologic response in light chain amyloidosis patients and methods of treating light chain amyloidosis using an approved drug product comprising daratumumab and hyaluronidase in combination with bortezomib, cyclophosphamide and dexamethasone. Also described are drug products containing daratumumab and hyaluronidase, and methods of selling or offering for sale a drug product comprising daratumumab and hyaluronidase.

公开(公告)号：US20230340145A1

公开(公告)日：2023-10-26

申请号：US18175345

申请日：2023-02-27

Applicant: Janssen Biotech, Inc.

Inventor： Tahamtan Ahmadi ,  Christopher Chiu ,  Ming Qi ,  Amy Sasser ,  Jordan Schecter

IPC: C07K16/28 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K39/395 ,  A61K9/00 ,  A61K31/454

CPC classification number: C07K16/2896 ,  A61P35/00 ,  A61K31/573 ,  A61K31/4439 ,  A61K31/69 ,  A61K39/3955 ,  A61K9/0019 ,  A61K31/454 ,  C07K2317/34 ,  C07K2317/565 ,  A61K2039/54

Abstract: Disclosed are methods of treating a subject having high-risk multiple myeloma, methods of achieving negative minimal residual disease status in a subject having multiple myeloma, and methods of predicting a likelihood of, or decreasing a risk of, relapse and/or disease progression in a subject having multiple myeloma.

公开(公告)号：US20220204638A1

公开(公告)日：2022-06-30

申请号：US17691050

申请日：2022-03-09

Applicant: Janssen Biotech, Inc.

Inventor： Xiangyang Liu ,  Jordan Schecter

IPC: C07K16/28 ,  C12N5/0775 ,  A61P35/00

Abstract: Disclosed herein are combination therapies comprising daratumumab and their uses.

公开(公告)号：US20200330594A1

公开(公告)日：2020-10-22

申请号：US16850360

申请日：2020-04-16

Applicant: Janssen Biotech, Inc.

Inventor： Xiangyang Liu ,  Jordan Schecter

IPC: A61K39/395 ,  A61K31/69 ,  A61K31/454 ,  A61K31/573 ,  A61K31/198 ,  A61K9/00 ,  A61P35/00

Abstract: Disclosed herein are combination therapies comprising daratumumab and their uses.